Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Wang, Jie
Zhong, Jia
Wu, Lin
Chen, Bolin
Wang, Zhe-Hai
Yao, Yu
Dong, Xiaorong
Li, Wei
Ren, Xiubao
Hou, Xiaoming
Zang, Ai-min
Qu, Xiujuan
Zhang, Guojun
Wang, Yongsheng
Bai, Yuansong
Liu, Linlin
Yu, Guohua
Chen, Xingwu
Ding, Lieming
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Hunan Canc Hosp, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Sch Med, Thorac Med Dept 2, Affiliated Canc Hosp, Changsha, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Changsha, Peoples R China
[5] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[6] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[7] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[8] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[9] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[10] Lanzhou Univ, Dept Med Oncol, Hosp 1, Lanzhou, Peoples R China
[11] Hebei Univ, Affiliated Hosp, Baoding, Peoples R China
[12] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China
[13] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[14] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[15] Jilin Univ, Dept Hematol & Oncol, China Japan Union Hosp, Changchun, Peoples R China
[16] Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China
[17] Weifang Peoples Hosp, Weifang, Shandong, Peoples R China
[18] Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Wuhu, Peoples R China
[19] Betta Pharmaceut Co Ltd, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8604
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
    Bossi, P.
    Minuti, G.
    Brana, I.
    Garcia, V. Moreno
    Boni, V.
    Jamme, P.
    Call, J. A.
    Yan, C.
    Barasa, B.
    Doze, P.
    Joe, A. K.
    Laus, G.
    Daste, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1610 - S1611
  • [2] Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
    Geuijen, Cecile
    di Matteo, Mario
    Gallenne, Tristan
    Cafarello, Sarah Trusso
    Nijhuis, Roy
    Visser, Therese
    Bartelink, Willem
    Bartelink-Clements, Carina
    Eppink, Berina
    Klooster, Rinse
    Dekruif, John
    Mazzone, Massimiliano
    Throsby, Mark
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [3] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
    Cappuzzo, F.
    Moreno Garcia, V.
    Ou, S-H. I.
    Brandao, M.
    Sanmamed, M. F.
    Helissey, C.
    Wislez, M.
    Call, J. A.
    Grisanti, S.
    Johnson, M. L.
    Boni, V.
    Jamme, P.
    Monnet, I.
    Siena, S.
    Yan, C.
    Barasa, B.
    Richard, B.
    Joe, A. K.
    Laus, G.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1671 - S1671
  • [4] Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer
    de Gorter, David J.
    O'Connor, Marie
    Deshiere, Alexandre
    van Rosmalen, Martijn
    Fatrai, Szabolcs
    van Bueren, Jeroen Lammerts
    Geuijen, Cecile A.
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
    Brandao, Mariana da Rocha Almeida
    Zugazagoitia, Jon
    Dingemans, Anne-Marie C.
    Duruisseaux, Michael
    Parent, Pauline
    Juan-Vidal, Oscar
    Spira, Alexander I.
    Vicier, Cecile
    Zalcman, Gerard
    Barasa, Ben
    Yan, Chris
    Doze, Petra
    Joe, Andrew K.
    Laus, Gianluca
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab
    de Gorter, David J. J.
    Deshiere, Alexandre
    Kramer, Arjen
    van Rosmalen, Martijn
    Mortensen, Franziska
    Geuijen, Cecile
    CANCER RESEARCH, 2023, 83 (07)
  • [7] The bispecific antibody MCLA-129 impairs NSCLC tumor growth by targeting EGFR and c-MET, inhibiting ligand-induced signaling and promoting ADCC and ADCP.
    de Gorter, David J.
    Deshiere, Alexandre
    van Rosmalen, Martijn
    Wohn, Christian
    Eppink, Berina
    Gallenne, Tristan
    Klooster, Rinse
    Mao, Li
    Xu, Wenxin
    Deng, Liang
    Shu, Qingyu
    Liu, Wei
    de Kruif, John
    Di Matteo, Mario
    Mazzone, Massimiliano
    Throsby, Mark
    Geuijen, Cecile A.
    CANCER RESEARCH, 2021, 81 (13)
  • [8] C-MET inhibitors for advanced non-small cell lung cancer
    Pasquini, Giulia
    Giaccone, Giuseppe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 363 - 375
  • [9] MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study
    Ou, S. H.
    Garcia, V. Moreno
    Bazo, I. Gil
    Prenen, H.
    Moreno, I.
    Johnson, M.
    Alvarez, E. Castanon
    Nagasaka, M.
    Adeyemi, S.
    Barasa, B.
    Bol, K.
    Doze, P.
    Engbers, A.
    Joe, A. K.
    Stalbovskaya, V.
    Laus, G.
    Call, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S122 - S122
  • [10] Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)
    Camidge, D. Ross
    Ou, Sai-Hong Ignatius
    Shapiro, Geoffrey
    Otterson, Gregory Alan
    Villaruz, Liza Cosca
    Villalona-Calero, Miguel Angel
    Iafrate, A. John
    Varella-Garcia, Marileila
    Dacic, Sanja
    Cardarella, Stephanie
    Zhao, Weiqiang
    Tye, Lesley
    Stephenson, Patricia
    Wilner, Keith D.
    James, Leonard Philip
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345